# US 2017/0281548 A1 · Organic Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281548 A1
- Document ID: US20170281548A1
- Status: Published application
- Kind: A1
- Application number: 15/627,619
- Filed: 2017-06-20
- Published: 2017-10-05
- Earliest claimed: 2002-11-19
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Holger PETERSEN; Olivier Jean LAMBERT; Rolf LÖFFLER; Michael AUSBORN; Jean-Daniel BONNY
- Web page: https://patentgrep.com/patent/US20170281548A1

## CPC

- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 5/02: of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P 5/08: for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition comprises octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane.

## Claims

### Claim 1

A process for the production of octreotide acetate microparticles, comprising the steps of:
a) forming a solution or dispersion by combining a first mixture which comprises octreotide acetate dissolved in a polar organic solvent that is miscible with methylene dichloride, with a second mixture which comprises a linear poly (lactide-co-glycolide) free from silicone oil or heptane dissolved in methylene chloride;
b) combining said solution or dispersion with an effective amount of an aqueous process medium to form an emulsion that contains said process medium and microdroplets which are free from silicone oil or heptane comprising said octreotide acetate, said methylene dichloride and said linear poly (lactide-co-glycolide); and
c) forming said microparticles by combining said emulsion with an effective amount of an extraction medium.

### Claim 2 (depends on 1)

A process of claim 1 wherein said polar organic solvent that is miscible with methylene dichloride is methanol.

### Claim 3 (depends on 1)

A process of claim 1 wherein said second mixture contains from about 1% to about 40% of linear poly (lactide-co-glycolide).

### Claim 4 (depends on 3)

A process of claim 3 wherein said second mixture contains from 2% to 2.5% of linear poly (lactide-co-glycolide).

### Claim 5 (depends on 1)

A process of claim 1 wherein said first mixture contains from about 1% to about 20% of octreotide acetate.

### Claim 6 (depends on 5)

A process of claim 5 wherein said first mixture contains from 4% to 10% of octreotide acetate.

### Claim 7 (depends on 6)

A process of claim 6 wherein said polar organic solvent that is miscible with methylene dichloride is methanol.

### Claim 8 (depends on 1)

A process of claim 1 wherein said aqueous process medium is water saturated with methylene dichloride.

### Claim 9 (depends on 8)

A process of claim 8 wherein said aqueous process medium comprises a stabilizing agent.

### Claim 10 (depends on 9)

A process of claim 9 wherein said stabilizing agent is selected from the group consisting of polyvinyl pyrolidone, carboxymethyl cellulose sodium, polyvinyl alcohol and gelatin.

### Claim 11 (depends on 9)

A process of claim 9 wherein said stabilizing agent is polyvinyl alcohol.

### Claim 12 (depends on 1)

A process of claim 1 wherein said extraction medium is aqueous.

### Claim 13 (depends on 12)

A process of claim 12 wherein said extraction medium is an aqueous sodium dihydrogen phosphate/disodium hydrogen phosphate buffer solution.

### Claim 14 (depends on 12)

A process of claim 12 wherein said extraction medium has a pH of 7 or higher.

### Claim 15 (depends on 12)

A process of claim 12 wherein said extraction medium is distilled water.

### Claim 16 (depends on 1)

A process of claim 1 wherein said linear poly (lactide-co-glycolide) has a molecular weight in the range from about 30,000 to 70,000 daltons.

### Claim 17 (depends on 1)

A pharmaceutical composition which comprises microparticles obtained according to the process of claim 1.

### Claim 18 (depends on 1)

Microparticles obtainable according to the process of claim 1.

### Claim 19 (depends on 18)

Microparticles of claim 18 which are free from silicone oil or heptane.
